<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82210">
  <stage>Registered</stage>
  <submitdate>14/08/2007</submitdate>
  <approvaldate>21/08/2007</approvaldate>
  <actrnumber>ACTRN12607000420448</actrnumber>
  <trial_identification>
    <studytitle>The Effect of the Antioxidant (GliSODin) on Unexplained Fatigue</studytitle>
    <scientifictitle>Evaluation of an orally-bioactive form of Superoxide Dismutase, GliSODin, in reducing levels of fatigue in otherwise healthy women aged between 50-65 years over a 12-week period.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Fatigue</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Superoxide dismutase enzyme in an orally-bioactive form, 250mg daily for 12 weeks.  The capsule contains 3.11mg melon extract in a base of maltodexrtin.</interventions>
    <comparator>Double-blind placebo-controlled, using an identical-looking 2-piece gel capsule containing maltodextrin, the same filler used in the active capsule.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Subjective markers of fatigue</outcome>
      <timepoint>12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Blood levels of endogenous antioxidant enzymes, Superoxide dismutase (SOD) and Glutathione peroxidase</outcome>
      <timepoint>Baseline, 6 weeks and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the effects of the intervention on several biochemical markers of oxidative stress, before during and after 12 weeks of treatment.</outcome>
      <timepoint>Baseline, 6 weeks and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the blood levels of stress-related hormones</outcome>
      <timepoint>Baseline, 6 weeks, 12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Unexplained fatigue of greater than 3 months' duration</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Clinical Depression, Diagnosed Thyroid Disorder, Iron-deficiency anaemia, Coeliac Disease, Any serious disease, History of Alcohol or Drug Abuse, Primary Sleep Disorder</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Randomisation conducted by the Hospital Pharmacy from which the medication is dispensed.  Eligibility for participation in the trial was conducted by personnel in Brisbane who will have no contact at any stage of the study with the personnel in Launceston Hospital who randomise the medication.  The capsules are dispensed in identical white plastic tablet bottles named for the study and identified only by numbers from 1-40.  The code is held by this off-site pharmacy in Launceston.</concealment>
    <sequence>Simple randomisation by using a randomisation table from a statistic book</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/07/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>4006</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Applied Science &amp; Nutrition</primarysponsorname>
    <primarysponsoraddress>34 Kingsholme Street,
New Farm   QLD</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>IsoCell NUTRA</fundingname>
      <fundingaddress>53 Boulevard du General Martial Valin, 74015, Paris, France</fundingaddress>
      <fundingcountry>France</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Applied Science &amp; Nutrition</fundingname>
      <fundingaddress>34 Kingsholme Street
New Farm   QLD   4006</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Cell-Logic Pty Ltd</sponsorname>
      <sponsoraddress>58 Kingston Drive
Helensvale   QLD  4212</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Fatigue is a common problem and in many cases its cause cannot be medically explained.  An understanding of the biochemical processes humans use to generate energy within the cells leads to a hypothesis to explain the cause of some forms of fatigue based on defective cellular energy processes.  The active substance used in this study, GliSODin contains Superoxide Dismutase, an enzyme which may assist in the normal biochemical production of energy in human cells.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Queensland</ethicname>
      <ethicaddress>University of Queensland,
Brisbane   QLD   4072</ethicaddress>
      <ethicapprovaldate>30/05/2007</ethicapprovaldate>
      <hrec>HMS07/3005</hrec>
      <ethicsubmitdate>28/05/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Christine Houghton</name>
      <address>12 Blackthorne Street,
Ormiston   QLD   4160</address>
      <phone>07 3488 0385</phone>
      <fax>07 3488 0389</fax>
      <email>choughton@regenesis.net.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Elizabeth Steels</name>
      <address>34 Kingsholme Street,
New Farm   QLD   4006</address>
      <phone>07 3254-2812</phone>
      <fax />
      <email>appliedscience@bigpond.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Christine Houghton</name>
      <address>12 Blackthorne Street,
Ormiston   QLD   4160</address>
      <phone>07 3488 0385</phone>
      <fax>07 3488 0389</fax>
      <email>choughton@regenesis.net.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>